Watching Quanterix; Traders Circulate Analyst Comments Suggesting The Preliminary CLFS Determinations For New Codes Was Just Published With Worse Than Expected Decisions For Neuro Diagnostics, The Advisory Panel Voted To Crosswalk To $130 For Tests Like Blood-Based pTau-217, CMS Disagreed And Recommended A Crosswalk To Just $17
Portfolio Pulse from Benzinga Newsdesk
Quanterix is facing potential challenges as the CMS recommended a lower crosswalk price of $17 for neuro diagnostics tests like blood-based pTau-217, contrary to the advisory panel's $130 recommendation. This could impact Quanterix's revenue from these tests.
September 26, 2024 | 4:47 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Quanterix may experience a negative impact on its revenue due to CMS's recommendation of a $17 crosswalk price for neuro diagnostics tests, which is significantly lower than the advisory panel's $130 recommendation.
The CMS's decision to recommend a lower crosswalk price than expected for neuro diagnostics tests directly affects Quanterix, as it could lead to reduced revenue from these tests. The advisory panel's higher recommendation was not followed, indicating a potential financial setback.
CONFIDENCE 95
IMPORTANCE 80
RELEVANCE 90